Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. (LCTX) generates a steady flow of news as a clinical-stage biotechnology company developing allogeneic, or “off the shelf,” cell therapies for serious medical conditions. News updates commonly highlight progress across its proprietary cell-based technology platform, clinical programs, manufacturing capabilities, and strategic collaborations.
Investors following LCTX news can expect coverage of clinical milestones from its lead programs, including OpRegen retinal pigment epithelial cell therapy for geographic atrophy secondary to age-related macular degeneration and OPC1 oligodendrocyte progenitor cell therapy for spinal cord injuries. Company announcements often describe data presentations from ongoing studies, such as long-term follow-up results from the OpRegen Phase 1/2a trial and updates from the GAlette Phase 2a study, as well as developments in the DOSED clinical study evaluating a novel delivery system for OPC1 in subacute and chronic spinal cord injury.
Lineage’s news flow also features preclinical and platform updates, including progress with ReSonance (ANP1), an auditory neuronal progenitor cell program for hearing loss under a research collaboration with William Demant Invest A/S, and initiatives such as PNC1 for potential treatment of vision loss and ILT1, an islet cell transplant program for Type 1 Diabetes. Additional releases may cover advances in its AlloSCOPE manufacturing platform, cGMP production runs from its two-tiered cell banking system, and gene-editing collaborations involving the RND1 hypoimmune induced pluripotent stem cell line.
Corporate news items include quarterly financial results, capital-raising transactions, and governance matters disclosed through press releases and SEC filings. For investors and observers interested in the evolution of allogeneic cell transplantation, the LCTX news page provides ongoing insight into Lineage’s clinical data, research collaborations, manufacturing achievements, and strategic direction.
Lineage (NYSE American: LCTX) received a novel gene-edited induced pluripotent stem cell (iPSC) line from Factor Bioscience on Jan 6, 2026 under their existing collaboration.
The hypoimmune line includes a targeted deletion of B2M, targeted insertion/overexpression of HLA-E, and a third undisclosed disease-specific edit. Acceptance triggered a success payment to Factor; an additional payment is contingent on Lineage taking an exclusive license. Lineage will further test the line for performance and compatibility with its AlloSCOPE manufacturing platform before deciding to license and advance programs.
Lineage Cell Therapeutics (NYSE American: LCTX) published a January 5, 2026 letter highlighting 2025 achievements and 2026 priorities. Key points include progress in the partnered OpRegen program for geographic atrophy (single-dose visual improvement reported lasting at least 3 years), Genentech opened 9 additional sites and obtained RMAT designation for OpRegen, receipt of the company’s first cash milestone toward up to $620 million in partner milestones, advancement of the proprietary AlloSCOPE manufacturing platform (two cGMP runs and a clinic-released product), a new ReSonance collaboration, a William Demant partnership, and launch of an islet cell initiative for Type 1 Diabetes.
Priorities for 2026: clinical readouts and milestones, manufacturing expansion, selective partnerships, and disciplined capital allocation.
Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 2025 results and a business update on November 6, 2025. Key items: a research collaboration with William Demant Invest providing up to $12 million for preclinical development of ReSonance (ANP1); cGMP production runs for OpRegen and OPC1 from a two-tier cell bank process enabling potential production of millions of doses; positive 36-month Phase 1/2a OpRegen clinical results featured at CTS 2025; first chronic spinal cord injury participant treated with OPC1 in the DOSED study with no significant safety events at 60 days. Financials: cash and marketable securities $40.5M as of Sept 30, 2025 (runway into Q2 2027) and Q3 net loss $29.8M ($0.13/sh), driven largely by a $26.6M non-cash fair value remeasurement of warrant liabilities.
Lineage Cell Therapeutics (NYSE American: LCTX) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 after U.S. market close. Management will host a conference call and live webcast on November 6, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to discuss results and provide a business update.
Dial-in for the call from the U.S. and Canada is (888) 596-4144 (request “Lineage Cell Therapeutics Call”). A live webcast will be available in the Investors section of Lineage’s website. Webcast replay will be available on the website for 30 days, and a telephone replay is available through November 14, 2025 at (800) 770-2030 using conference ID 3958367.
Lineage Cell Therapeutics (NYSE American: LCTX) has launched a new islet cell transplant program targeting Type 1 Diabetes (T1D). The company's primary focus is addressing the manufacturing scale challenges in islet cell production, aiming to establish a dynamic culturing system that can support large-scale production.
CEO Brian M. Culley highlighted that while several islet cell programs have reached Phase 1 clinical trials, the industry faces significant challenges in manufacturing sufficient material for the addressable patient population. The company plans to leverage its GMP manufacturing capabilities to develop a production system capable of generating hundreds of millions of cells per patient.
The initiative will begin with testing their proprietary cell line, marking their third unique master cell bank at their in-house facility. Future plans include demonstrating system compatibility with hypo-immune cell lines for clinical T1D applications.
Lineage Cell Therapeutics (NYSE:LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological and ophthalmic conditions, has announced upcoming investor conference presentations.
CEO Brian M. Culley will present at two major healthcare conferences: the H.C. Wainwright Global Investment Conference on September 8, 2025, at 11:30am ET, and Baird's Global Healthcare Conference on September 9, 2025, at 12:50pm ET. A replay of the H.C. Wainwright presentation will be available on the company's website after the event.
Lineage Cell Therapeutics (NYSE American: LCTX) has entered into a significant research collaboration with William Demant Invest A/S (WDI) to develop ReSonance™ (ANP1), a novel cell therapy for hearing loss. The partnership includes up to $12 million in funding from WDI over a three-year term to advance preclinical development.
The collaboration will combine Lineage's cell manufacturing expertise with hearing loss research from Eriksholm Research Centre. The development activities will cover cell manufacturing, proof-of-concept studies, delivery development, and regulatory strategy to support potential IND/CTA filing.
ReSonance represents Lineage's first internally-developed cell transplant program, targeting auditory nerve cell restoration for the 2.5 billion people expected to experience hearing loss by 2025. The therapy aims to treat auditory neuropathy by replacing damaged auditory nerve cells to restore hearing and potentially enhance cochlear implant effectiveness.
Lineage Cell Therapeutics (NYSE:LCTX) reported Q2 2025 financial results and significant clinical progress. The company highlighted positive 36-month results from the OpRegen Phase 1/2a trial, showing sustained benefits in treating geographic atrophy, with treated patients demonstrating a mean improvement of +6.2 letters in vision acuity.
Key financial metrics include $42.3 million in cash reserves supporting operations into Q1 2027, revenues of $2.8 million (up from $1.4M YoY), and a net loss of $30.5 million. The company achieved manufacturing milestones and treated its first chronic patient in the OPC1 spinal cord injury program.
The quarter was marked by a $14.8 million impairment charge related to the VAC platform and increased warrant liability expenses due to share price appreciation.Lineage Cell Therapeutics (NYSE American: LCTX), a clinical-stage biotechnology company focused on allogeneic cell therapies for neurological conditions, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after U.S. market close.
The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Investors can access the call by dialing (800) 715-9871 from the U.S. and Canada. A webcast replay will be available for 30 days, and a telephone replay through August 19, 2025, can be accessed using conference ID 7788342.
Lineage Cell Therapeutics (NYSE:LCTX) has announced a significant milestone in its DOSED clinical study with the first-ever treatment of a chronic spinal cord injury patient using OPC1 cells and a new parenchymal spinal delivery system at UC San Diego Health.
The study will evaluate both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) spinal cord injury patients. The first patient, with a complete SCI injury (AIS grade A), successfully received a one-time injection of 10 million OPC1 cells. OPC1, an allogeneic stem cell-derived cell transplant, aims to restore or enhance functional activity in SCI patients by replacing damaged cells.
The treatment builds on extensive safety data from two previous clinical trials, including a 5-patient Phase 1 trial with 13+ years of follow-up and a 25-patient Phase 1/2a trial with 7+ years of monitoring, both showing no unexpected serious adverse events.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
